Date published: 2026-5-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

ET-1 Inhibitors

ET-1 inhibitors belong to a specific chemical class of compounds meticulously designed to modulate the activity of endothelin-1 (ET-1), a peptide hormone involved in various physiological processes, including vasoconstriction, cell proliferation, and inflammation. ET-1 plays a significant role in regulating blood vessel constriction and dilation, as well as influencing cellular responses in multiple tissues. These inhibitors are thoughtfully crafted molecules engineered to interact with ET-1, influencing its normal function. Through these interactions, they might impact various cellular processes associated with vasoactivity and cellular signaling, without directly altering its peptide structure or its involvement in downstream pathways. The design of ET-1 inhibitors is grounded in a comprehensive understanding of the structural and functional attributes of the peptide hormone. Typically developed using advanced chemical synthesis methods and informed by insights from molecular biology and cellular signaling pathways, these inhibitors are characterized by their ability to selectively bind to ET-1. This selectivity enables focused modulation of cellular pathways that rely on the activity of this specific hormone. The development and utilization of ET-1 inhibitors contribute to advancing our understanding of the complex interplay between peptide hormone-mediated signaling and physiological responses, offering insights into the fundamental molecular mechanisms that govern vascular tone, cellular proliferation, and tissue responses to changes in ET-1 activity.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bosentan

147536-97-8sc-210957
10 mg
$195.00
3
(1)

This dual endothelin receptor antagonist (ERA) is investigated for its use in regard to pulmonary arterial hypertension.

Ambrisentan

177036-94-1sc-207276
5 mg
$348.00
(0)

Another selective endothelin receptor antagonist used for pulmonary arterial hypertension.

Sitaxsentan Sodium

210421-74-2sc-215857
10 mg
$640.00
(0)

A selective endothelin receptor antagonist that was previously approved for pulmonary arterial hypertension but has been withdrawn from the market.

Atrasentan Hydrochloride

195733-43-8sc-503157
50 mg
$490.00
(0)

It is an endothelin receptor antagonist being studied for its potential in diabetic kidney disease and prostate cancer.

BQ-123, Sodium Salt

136655-57-7sc-391073
sc-391073A
1 mg
5 mg
$123.00
$418.00
1
(0)

A selective endothelin receptor antagonist primarily targeting the endothelin A receptor.

CI 1020

162256-50-0sc-204687
sc-204687A
10 mg
50 mg
$175.00
$793.00
(0)

A non-peptide endothelin receptor antagonist with a preference for the endothelin A receptor.

Zibotentan

186497-07-4sc-364662
sc-364662A
5 mg
10 mg
$340.00
$640.00
(0)

It is an endothelin receptor antagonist that has been studied for prostate cancer.

Lixivaptan

168079-32-1sc-489378
5 mg
$84.00
(0)

While not a direct ET-1 inhibitor, lixivaptan is a vasopressin V2 receptor antagonist that indirectly affects the ET-1 pathway by modulating fluid balance.